Cor Vasa 2010, 52(11-12):713-720 | DOI: 10.33678/cor.2010.177

Antibody-mediated rejection after heart transplantation - an overview of current concepts

Tomáš Gazdič*, Ivan Málek, Josef Kautzner
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika

A factor shown to heavily impact the prognosis of heart transplant recipients is absence of rejection, i.e., the failure of the body to accept a transplanted tissue. Historically, a better characterized and more readily treatable type is cellular rejection which has been at the forefront of research and interest over the past 45 years. There has been an appreciable renewal of interest in antibody-mediated rejection after graft dysfunction up to graft failure in the early post-transplant period had been shown to be causally related to transplant coronary artery disease at a later time. This review article aims at keeping the reader up to date about current options in diagnosing and treating antibody-mediated rejection.

Keywords: Heart transplantation; Antibody-mediated rejection; Diagnosis; Treatment

Published: November 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gazdič T, Málek I, Kautzner J. Antibody-mediated rejection after heart transplantation - an overview of current concepts. Cor Vasa. 2010;52(11-12):713-720. doi: 10.33678/cor.2010.177.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) 2009;23:34-46. Go to original source... Go to PubMed...
    2. Cai J, Terasaki PI. Incidence and role of antibody in graft injury: how can it best be monitored? Transplant Rev 2004;18:192-203. Go to original source...
    3. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003;3: 665-673. Go to original source... Go to PubMed...
    4. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003;22:58-69. Go to original source... Go to PubMed...
    5. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004;4:438-443. Go to original source... Go to PubMed...
    6. Freudenberger RS, Tawfik I, Shinnar M, Pendergast T. Panel-reactive screening and treatment practices following bridge to transplantation ventricular assist device placement. Transplant Proc 2009;41:1813-1815. Go to original source... Go to PubMed...
    7. Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 1997;64:1120-1125. Go to original source... Go to PubMed...
    8. Wright EJ, Fiser WP, Edens RE, et al. Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch. J Heart Lung Transplant 2007;26:1163-1169. Go to original source... Go to PubMed...
    9. George I, Colley P, Russo MJ, et al. Association of device surface and biomaterials with immunologic sensitization after mechanical support. J Thorac Cardiovasc Surg 2008;135:1372-1379. Go to original source... Go to PubMed...
    10. Harada H, Togashi M, Seki T, et al. Hyperacute onset of haemolytic-uraemic syndrome associated with hyperacute rejection in the recipient of an ABO-incompatible kidney. Nephrol Dial Transplant 2003;18:1009-1012. Go to original source... Go to PubMed...
    11. Montgomery RA. ABO incompatible transplantation: to B or not to B. Am J Transplant 2004;4:1011-1012. Go to original source... Go to PubMed...
    12. Zwirner NW, Fernandez-Vina MA, Stastny P. MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 1998;47:139-148. Go to original source... Go to PubMed...
    13. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001;71:886-892. Go to original source... Go to PubMed...
    14. Warraich RS, Pomerance A, Stanley A, et al. Cardiac myosin autoantibodies and acute rejection after heart transplantation in patients with dilated cardiomyopathy. Transplantation 2000;69:1609-1617. Go to original source... Go to PubMed...
    15. Latif N, Rose ML, Yacoub MH, Dunn MJ. Association of pretransplantation antiheart antibodies with clinical course after heart transplantation. J Heart Lung Transplant 1995;14:119-126.
    16. Hardy S, Lee SH, Terasaki PI. Sensitization 2001. Clin Transpl 2001:271-278. Go to PubMed...
    17. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006;25:153-159. Go to original source... Go to PubMed...
    18. Lynch RJ, Platt JL. Accommodation in organ transplantation. Curr Opin Organ Transplant 2008;13:165-170. Go to original source... Go to PubMed...
    19. Everly MJ, Terasaki PI. Monitoring and treating posttransplant human leukocyte antigen antibodies. Hum Immunol 2009;70:655-659. Go to original source... Go to PubMed...
    20. Rose ML. De novo production of antibodies after heart or lung transplantation should be regarded as an early warning system. J Heart Lung Transplant 2004;23:385-395. Go to original source... Go to PubMed...
    21. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735-739. Go to original source... Go to PubMed...
    22. Fuller TC, Fuller AA, Golden M, Rodey GE. HLA alloantibodies and the mechanism of the antiglobulin-augmented lymphocytotoxicity procedure. Hum Immunol 1997;56:94-105. Go to original source... Go to PubMed...
    23. Cicciarelli J, Helstab K, Mendez R. Flow cytometry PRA, a new test that is highly correlated with graft survival. Clin Transplant 1992;6:159-164.
    24. Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum Immunol 1998;59:313-322. Go to original source... Go to PubMed...
    25. Pei R, Lee J, Chen T, et al. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 1999;60:1293-1302. Go to original source... Go to PubMed...
    26. Kaufman A, de Souza Pontes LF, Queiroz Marques MT, et al. Analysis of AHG-PRA and ELISA-PRA in kidney transplant patients with acute rejection episodes. Transpl Immunol 2003;11:175-178. Go to original source... Go to PubMed...
    27. Cesbron-Gautier A, Simon P, Achard L, et al. [Luminex technology for HLA typing by PCR-SSO and identification of HLA antibody specificities.] Ann Biol Clin (Paris) 2004;62:93-98.
    28. Betkowski AS, Graff R, Chen JJ, Hauptman PJ. Panel-reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant 2002;21:644-650. Go to original source... Go to PubMed...
    29. Lavee J, Kormos RL, Duquesnoy RJ, et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 1991;10:921-929; discussion 929-930.
    30. Nwakanma LU, Williams JA, Weiss ES, et al. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 2007;84:1556-1562; discussion 1562-1563. Go to original source... Go to PubMed...
    31. Ballew CC, Bergin JD. Management of patients with preformed reactive antibodies who are awaiting cardiac transplantation. Am J Crit Care 2005;14:46-51. Go to original source...
    32. Kobashigawa J, Mehra M, West L, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 2009;28:213-225. Go to original source... Go to PubMed...
    33. Terasaki PI, Marchioro TL, Strazl TE. Sero-typing of human lymphocyte antigens: preliminary trials on long-term kidney homograft survivors. In: Council NAoS-NR, ed. Histocompatibility Testing. Washington, DC: National Academy Sciences, 1965:83-96.
    34. Pelletier RP, Adams PW, Hennessy PK, Orosz CG. Comparison of crossmatch results obtained by ELISA, flow cytometry, and conventional methodologies. Hum Immunol 1999;60:855-861. Go to original source... Go to PubMed...
    35. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003;76:631-636. Go to original source... Go to PubMed...
    36. Stehlik J, Islam N, Hurst D, et al. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J Heart Lung Transplant 2009;28:1129-1134. Go to original source... Go to PubMed...
    37. Yang J, Schall C, Smith D, et al. HLA sensitization in pediatric pre-transplant cardiac patients supported by mechanical assist devices: the utility of Luminex. J Heart Lung Transplant 2009;28:123-129. Go to original source... Go to PubMed...
    38. Olerup O, Zetterquist H. HLA-DRB1*01 subtyping by allele-specific PCR amplification: a sensitive, specific, and rapid technique. Tissue Antigens 1991;37:197-204. Go to original source... Go to PubMed...
    39. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: the emory algorithm. Am J Transplant 2006;6:2307-2315. Go to original source... Go to PubMed...
    40. Suciu-Foca N, Reed E, Marboe C, et al. The role of anti-HLA antibodies in heart transplantation. Transplantation 1991;51:716-724. Go to original source... Go to PubMed...
    41. Rose EA, Pepino P, Barr ML, et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 1992;11:S120-S123.
    42. Sundaresan S, Mohanakumar T, Smith MA, et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998;65:648-653. Go to original source... Go to PubMed...
    43. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002;74:799-804. Go to original source... Go to PubMed...
    44. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009;9:1063-1071. Go to original source... Go to PubMed...
    45. Ho EK, Vlad G, Colovai AI, et al. Alloantibodies in heart transplantation. Hum Immunol 2009;70:825-829. Go to original source... Go to PubMed...
    46. Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005;17:541-545. Go to original source... Go to PubMed...
    47. Feucht HE. Complement C4d in graft capillaries-the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003;3:646-652. Go to original source... Go to PubMed...
    48. Loy TS, Bulatao IS, Darkow GV, et al. Immunostaining of cardiac biopsy specimens in the diagnosis of acute vascular (humoral) rejection: a control study. J Heart Lung Transplant 1993;12:736-740.
    49. Cecka M. Clinical outcome of renal transplantation. Factors influencing patient and graft survival. Surg Clin North Am 1998;78:133-148. Go to original source... Go to PubMed...
    50. Nishikawa K, Terasaki PI. Outcome of preemptive renal transplantation versus waiting time on dialysis. Clin Transpl 2002:367-377. Go to PubMed...
    51. Takemoto S. Sensitization and crossmatch. Clin Transpl 1995:417-432. Go to PubMed...
    52. Takahashi K, Saito K, Takahara S, et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004;4:1089-1096. Go to original source... Go to PubMed...
    53. Ramzy D, Rao V, Brahm J, et al. Cardiac allograft vasculopathy: a review. Can J Surg 2005;48:319-327.
    54. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008;69:591-604. Go to original source... Go to PubMed...
    55. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858. Go to original source... Go to PubMed...
    56. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110:2694-2700. Go to original source... Go to PubMed...
    57. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007;116:2726-2733. Go to original source... Go to PubMed...
    58. Zakliczynski M, Swierad M, Nozynski J, et al. Survival benefit in heart transplant recipients who have coronary artery disease confirmed using angiography and are receiving sirolimus. Transplant Proc 2009;41:285-288. Go to original source... Go to PubMed...
    59. Delgado JF, Manito N, Segovia J, et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev (Orlando) 2009;23:69-79. Go to original source... Go to PubMed...
    60. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007;83:1277-1280. Go to original source... Go to PubMed...
    61. Aranda JM, Jr., Scornik JC, Normann SJ, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 2002;73:907-910. Go to original source... Go to PubMed...
    62. Baran DA, Lubitz S, Alvi S, et al. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant Proc 2004;36:3164-3166. Go to original source... Go to PubMed...
    63. Luo H, Wu Y, Qi S, et al. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001;72:196-202. Go to original source... Go to PubMed...
    64. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008;86:1754-1761. Go to original source... Go to PubMed...
    65. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009;9:201-209. Go to original source... Go to PubMed...
    66. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009;87:1555-1561. Go to original source... Go to PubMed...
    67. Hickstein H, Korten G, Bast R, et al. Immunoadsorption of sensitized kidney transplant candidates immediately prior to surgery. Clin Transplant 2002;16:97-101. Go to original source... Go to PubMed...
    68. Abraham KA, Brown C, Conlon PJ, et al. Plasmapheresis as rescue therapy in accelerated acute humoral rejection. J Clin Apher 2003;18:103-110. Go to original source... Go to PubMed...
    69. Alarabi A, Backman U, Wikstrom B, et al. Plasmapheresis in HLA-immunosensitized patients prior to kidney transplantation. Int J Artif Organs 1997;20:51-56. Go to original source...
    70. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 2001;20:316-321. Go to original source... Go to PubMed...
    71. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004;8:535-542. Go to original source... Go to PubMed...
    72. Moger V, Ravishankar MS, Sakhuja V, et al. Intravenous immunoglobulin: a safe option for treatment of steroid-resistant rejection in the presence of infection. Transplantation 2004;77:1455-1456. Go to original source... Go to PubMed...
    73. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999;18:701-706. Go to original source... Go to PubMed...
    74. Leech SH, Rubin S, Eisen HJ, et al. Cardiac transplantation across a positive prospective lymphocyte cross-match in sensitized recipients. Clin Transplant 2003;17(Suppl 9):17-26. Go to original source... Go to PubMed...
    75. Kfoury AG, Hammond ME. Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. J Heart Lung Transplant 2010;29:389-394. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes